TWI546303B - 氮雜吲唑(azaindazole)或二氮雜吲唑(diazaindazole)類型之衍生物供作藥物之用途 - Google Patents

氮雜吲唑(azaindazole)或二氮雜吲唑(diazaindazole)類型之衍生物供作藥物之用途 Download PDF

Info

Publication number
TWI546303B
TWI546303B TW101102531A TW101102531A TWI546303B TW I546303 B TWI546303 B TW I546303B TW 101102531 A TW101102531 A TW 101102531A TW 101102531 A TW101102531 A TW 101102531A TW I546303 B TWI546303 B TW I546303B
Authority
TW
Taiwan
Prior art keywords
aromatic
compound
group
formula
mmol
Prior art date
Application number
TW101102531A
Other languages
English (en)
Chinese (zh)
Other versions
TW201247664A (en
Inventor
艾爾巴契爾 卡隆
凱琳 貝傑果萊
瑞米 雷柏特
安娜 克魯茲斯奇
菲利普 史密特
米契爾 皮瑞滋
尼可拉斯 雷希爾
Original Assignee
皮爾法伯製藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 皮爾法伯製藥公司 filed Critical 皮爾法伯製藥公司
Publication of TW201247664A publication Critical patent/TW201247664A/zh
Application granted granted Critical
Publication of TWI546303B publication Critical patent/TWI546303B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW101102531A 2011-01-27 2012-01-20 氮雜吲唑(azaindazole)或二氮雜吲唑(diazaindazole)類型之衍生物供作藥物之用途 TWI546303B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1150651A FR2970967B1 (fr) 2011-01-27 2011-01-27 Derives de type azaindazole ou diazaindazole comme medicament

Publications (2)

Publication Number Publication Date
TW201247664A TW201247664A (en) 2012-12-01
TWI546303B true TWI546303B (zh) 2016-08-21

Family

ID=44318089

Family Applications (1)

Application Number Title Priority Date Filing Date
TW101102531A TWI546303B (zh) 2011-01-27 2012-01-20 氮雜吲唑(azaindazole)或二氮雜吲唑(diazaindazole)類型之衍生物供作藥物之用途

Country Status (30)

Country Link
US (2) US20130172360A1 (US07794700-20100914-C00125.png)
EP (1) EP2668184B1 (US07794700-20100914-C00125.png)
JP (1) JP5931926B2 (US07794700-20100914-C00125.png)
KR (2) KR20180122028A (US07794700-20100914-C00125.png)
CN (1) CN103339129B (US07794700-20100914-C00125.png)
AR (1) AR084935A1 (US07794700-20100914-C00125.png)
AU (1) AU2012210467B2 (US07794700-20100914-C00125.png)
CA (1) CA2823824C (US07794700-20100914-C00125.png)
CY (1) CY1120088T1 (US07794700-20100914-C00125.png)
DK (1) DK2668184T3 (US07794700-20100914-C00125.png)
ES (1) ES2661695T3 (US07794700-20100914-C00125.png)
FR (1) FR2970967B1 (US07794700-20100914-C00125.png)
HK (1) HK1186737A1 (US07794700-20100914-C00125.png)
HR (1) HRP20180524T1 (US07794700-20100914-C00125.png)
HU (1) HUE037153T2 (US07794700-20100914-C00125.png)
IL (2) IL227496B (US07794700-20100914-C00125.png)
LT (1) LT2668184T (US07794700-20100914-C00125.png)
MA (1) MA34903B1 (US07794700-20100914-C00125.png)
MX (1) MX356411B (US07794700-20100914-C00125.png)
MY (1) MY180666A (US07794700-20100914-C00125.png)
PL (1) PL2668184T3 (US07794700-20100914-C00125.png)
PT (1) PT2668184T (US07794700-20100914-C00125.png)
RS (1) RS57101B1 (US07794700-20100914-C00125.png)
RU (1) RU2600976C2 (US07794700-20100914-C00125.png)
SI (1) SI2668184T1 (US07794700-20100914-C00125.png)
TN (1) TN2013000293A1 (US07794700-20100914-C00125.png)
TR (1) TR201802944T4 (US07794700-20100914-C00125.png)
TW (1) TWI546303B (US07794700-20100914-C00125.png)
UA (1) UA109698C2 (US07794700-20100914-C00125.png)
WO (1) WO2012101239A1 (US07794700-20100914-C00125.png)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
FR2970967B1 (fr) * 2011-01-27 2013-02-15 Pf Medicament Derives de type azaindazole ou diazaindazole comme medicament
JP6302846B2 (ja) 2012-02-22 2018-03-28 サンフォード−バーンハム メディカル リサーチ インスティテュート Tnap阻害剤としてのスルホンアミド化合物およびその使用
CN107383009B (zh) 2012-06-13 2020-06-09 因塞特控股公司 作为fgfr抑制剂的取代的三环化合物
EP2689779A1 (en) * 2012-07-27 2014-01-29 Pierre Fabre Medicament Derivatives of azaindazole or diazaindazole type for treating a cancer overexpressing trk
EP2689778A1 (en) * 2012-07-27 2014-01-29 Pierre Fabre Medicament Derivatives of azaindoles or diazaindoles for treating pain
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
CN105263931B (zh) 2013-04-19 2019-01-25 因赛特公司 作为fgfr抑制剂的双环杂环
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US10336707B2 (en) 2014-12-16 2019-07-02 Eudendron S.R.L. Heterocyclic derivatives modulating activity of certain protein kinases
EP3617205B1 (en) 2015-02-20 2021-08-04 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US10211205B2 (en) * 2016-04-27 2019-02-19 International Business Machines Corporation Field effect transistor structure for reducing contact resistance
CN108570052A (zh) * 2017-03-13 2018-09-25 中国科学院上海药物研究所 五元杂环并吡嗪化合物、制备方法、中间体、组合和应用
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
JP2021523118A (ja) 2018-05-04 2021-09-02 インサイト・コーポレイションIncyte Corporation Fgfr阻害剤の塩
US11466004B2 (en) 2018-05-04 2022-10-11 Incyte Corporation Solid forms of an FGFR inhibitor and processes for preparing the same
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
EP3725777A1 (en) * 2019-04-17 2020-10-21 Rottapharm Biotech S.r.l. Benzo- and pyrido-pyrazoles as protein kinase inhibitors
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
AU2020366006A1 (en) 2019-10-14 2022-04-21 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
BR112022010664A2 (pt) 2019-12-04 2022-08-16 Incyte Corp Derivados de um inibidor de fgfr
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021197467A1 (zh) * 2020-04-02 2021-10-07 上海华汇拓医药科技有限公司 多靶点的抗肿瘤化合物及其制备方法和应用
US20240018153A1 (en) 2020-11-20 2024-01-18 2692372 Ontario, Inc. Benzenesulfonamide derivatives and uses thereof
JP2024522189A (ja) 2021-06-09 2024-06-11 インサイト・コーポレイション Fgfr阻害剤としての三環式ヘテロ環

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0970084T3 (da) * 1997-03-19 2003-09-29 Abbott Gmbh & Co Kg Pyrrolo[2,3-d]pyrimidiner og deres anvendelse som inhibitorer for tyrosinkinase
EP1215208B1 (en) 1997-10-27 2006-07-12 Agouron Pharmaceuticals, Inc. 4-Aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases
ATE272626T1 (de) 2000-06-22 2004-08-15 Pfizer Verfahren zur herstellung von pyrazolopyrimidinonen
AU2003245700A1 (en) * 2002-02-12 2003-09-04 Glaxo Group Limited Pyrazolopyridine derivatives
DE102004061288A1 (de) * 2004-12-14 2006-06-29 Schering Ag 3-Amino-Pyrazolo[3,4b]pyridine als Inhibitoren von Proteintyrosinkinasen, deren Herstellung und Verwendung als Arzneimittel
RU2008110941A (ru) * 2005-08-25 2009-09-27 Ф.Хоффманн-Ля Рош Аг (Ch) ИНГИБИТОРЫ КИНАЗЫ p38 МАР И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
US20100056516A1 (en) 2006-07-17 2010-03-04 Williams Peter D 1-hydroxy naphthyridine compounds as anti-hiv agents
CN101594862B (zh) 2006-12-20 2015-11-25 内尔维阿诺医学科学有限公司 作为激酶抑制剂的取代吲唑衍生物
CA2693901C (en) 2007-07-20 2015-12-29 Nerviano Medical Sciences S.R.L. Substituted indazole derivatives active as kinase inhibitors
ES2630026T3 (es) 2008-12-18 2017-08-17 Nerviano Medical Sciences S.R.L. Derivados indazólicos sustituidos activos como inhibidores de cinasa
FR2970967B1 (fr) * 2011-01-27 2013-02-15 Pf Medicament Derives de type azaindazole ou diazaindazole comme medicament

Also Published As

Publication number Publication date
TR201802944T4 (tr) 2018-03-21
MX356411B (es) 2018-05-24
WO2012101239A1 (en) 2012-08-02
ES2661695T3 (es) 2018-04-03
IL257748B (en) 2020-06-30
RU2013138624A (ru) 2015-03-10
TW201247664A (en) 2012-12-01
US8883821B2 (en) 2014-11-11
JP5931926B2 (ja) 2016-06-08
RU2600976C2 (ru) 2016-10-27
MA34903B1 (fr) 2014-02-01
CN103339129A (zh) 2013-10-02
RS57101B1 (sr) 2018-06-29
CN103339129B (zh) 2015-07-29
PT2668184T (pt) 2018-03-13
IL227496A0 (en) 2013-09-30
IL257748A (en) 2018-04-30
US20130085144A1 (en) 2013-04-04
MX2013008673A (es) 2013-12-02
TN2013000293A1 (en) 2015-01-20
CA2823824C (en) 2018-12-11
NZ614432A (en) 2015-03-27
EP2668184B1 (en) 2018-01-10
AU2012210467B2 (en) 2016-07-07
MY180666A (en) 2020-12-04
FR2970967B1 (fr) 2013-02-15
EP2668184A1 (en) 2013-12-04
DK2668184T3 (en) 2018-03-12
FR2970967A1 (fr) 2012-08-03
SI2668184T1 (en) 2018-06-29
AR084935A1 (es) 2013-07-10
KR101923751B1 (ko) 2018-11-29
LT2668184T (lt) 2018-04-10
US20130172360A1 (en) 2013-07-04
JP2014503574A (ja) 2014-02-13
KR20180122028A (ko) 2018-11-09
PL2668184T3 (pl) 2018-06-29
CY1120088T1 (el) 2018-12-12
UA109698C2 (xx) 2015-09-25
AU2012210467A1 (en) 2013-09-12
HK1186737A1 (en) 2014-03-21
HRP20180524T1 (hr) 2018-05-04
KR20140014147A (ko) 2014-02-05
CA2823824A1 (en) 2012-08-02
IL227496B (en) 2019-02-28
HUE037153T2 (hu) 2018-08-28

Similar Documents

Publication Publication Date Title
TWI546303B (zh) 氮雜吲唑(azaindazole)或二氮雜吲唑(diazaindazole)類型之衍生物供作藥物之用途
JP6732855B2 (ja) 疼痛を治療するためのアザインダゾールまたはジアザインダゾール型の誘導体
US9428510B2 (en) Derivatives of azaindazole or diazaindazole type for treating a cancer overexpressing Trk
BR112013018852B1 (pt) Derivados do tipo azaindazol ou diazaindazol, seus usos na preparação de fármacos, métodos de preparação dos mesmos, e composições farmacêuticas compreendendo os referidos compostos
OA16493A (en) Derivatives of azaindazole or diazaindazole type as medicament.
NZ614432B2 (en) Derivatives of azaindazole or diazaindazole type as medicament